Ornidazole is an antibiotic used to treat protozoan infections. A synthetic nitroimidazole, it is commercially obtained from an acid-catalyzed reaction between 2-methyl-5-nitroimidazole and epichlorohydrin and is chemically identical to chloro-secnidazole. As a nitroimidazole it acts via enzymatic reduction of the nitro group under anaerobic or low oxygen conditions to generate reactive intermediates that damage microbial DNA and inhibit nucleic acid synthesis. The API is typically isolated as a crystalline solid with good chemical stability under dry, neutral to slightly acidic conditions and is assayed by reversed-phase HPLC and UV detection for potency and purity. Typical formulation considerations include limited aqueous solubility, pH dependent stability, and the need to control residual reagents from the epichlorohydrin route. Standard quality control includes identification by IR and NMR, assay by HPLC to pharmacopeial limits, water content by Karl Fischer, and residual solvent and genotoxic impurity evaluation according to current regulatory guidance.
Parent: Ornidazole
Parent: Ornidazole
Parent: Tinidazole / Metronidazole / Ornidazole
Related substances for ornidazole are monitored by validated HPLC methods and include unreacted 2-methyl-5-nitroimidazole, secnidazole-related positional isomers, dehalogenated and hydroxylated derivatives, oxidative degradation products, and process-related residuals such as epichlorohydrin and its transformation products. In commercial API specifications individual related compounds are commonly controlled at low levels with typical acceptance criteria of not more than about 0.3 percent for any single specified impurity and total impurities controlled to about 1.0 percent, while reporting thresholds for unidentified impurities are generally set at 0.05 percent or per ICH guidelines. Epichlorohydrin and other potential genotoxic impurities are managed to trace levels and kept at parts per million or lower in the final material in line with ICH M7 and related regulatory limits, and stability studies define additional impurity limits under accelerated and long term storage conditions.
Ornidazole is used to treat infections caused by protozoa and certain anaerobic bacteria, including trichomoniasis, giardiasis, and amoebic dysentery, as well as some mixed anaerobic infections when indicated by a clinician.
Ornidazole can be effective for loose motion if the cause is a susceptible protozoan pathogen such as Giardia lamblia or Entamoeba histolytica, but it is not appropriate for most viral or non-protozoal bacterial causes of acute diarrhea; clinical diagnosis and laboratory testing should guide therapy.
No, ornidazole does not treat yeast infections because those are fungal and typically caused by Candida species; antifungal agents are required for yeast infections.
Both are nitroimidazole antimicrobials with similar mechanisms of action against anaerobic organisms and protozoa, but they differ chemically and pharmacokinetically; ornidazole generally has a longer half life allowing less frequent dosing and is produced via different side chain chemistry, while metronidazole is more widely used and studied, so choice between them depends on local guidelines, dosing convenience, and specific clinical considerations.
